Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ropivacaine
Drug ID BADD_D02416
Description Ropivacaine is an aminoamide local anaesthetic drug commonly marketed by AstraZeneca under the trade name Naropin. It is present as a racemic mixture of the enantiomers containing equal proportions of the “S” and “R” forms. The marketed form contains the single S-enantiomer as the active ingredient.
Indications and Usage Used in obstetric anesthesia and regional anesthesia for surgery.
Marketing Status approved
ATC Code N01BB09
DrugBank ID DB00296
KEGG ID D08490
MeSH ID D000077212
PubChem ID 175805
TTD Drug ID D09RHQ
NDC Product Code 76339-126; 29902-0022
UNII 7IO5LYA57N
Synonyms Ropivacaine | 1-Propyl-2',6'-pipecoloxylidide | 1 Propyl 2',6' pipecoloxylidide | Naropin | Ropivacaine Monohydrochloride | Ropivacaine Hydrochloride | AL 381 | AL-381 | AL381 | Naropeine | LEA 103 | LEA-103 | LEA103 | Ropivacaine Monohydrochloride, (S)-isomer
Chemical Information
Molecular Formula C17H26N2O
CAS Registry Number 84057-95-4
SMILES CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neurotoxicity17.02.10.002; 12.03.01.0110.000179%Not Available
Pain08.01.08.0040.001965%
Paresis17.01.04.0080.000268%Not Available
Respiratory distress22.02.01.0120.000268%Not Available
Seizure17.12.03.0010.000893%
Sinus tachycardia02.03.03.0100.000179%
Stridor22.04.02.0030.000179%
Tachycardia02.03.02.0070.000357%Not Available
Therapeutic response decreased08.06.01.0160.000179%Not Available
Tremor17.01.06.0020.000875%
Haemorrhage24.07.01.0020.000179%Not Available
Adverse event08.06.01.0100.000268%Not Available
Stress cardiomyopathy24.04.04.026; 02.04.01.0120.000179%Not Available
Phrenic nerve paralysis17.01.04.0240.000179%Not Available
Therapeutic product effect decreased08.06.01.0500.002661%Not Available
Therapeutic product effect delayed08.06.01.0510.001215%Not Available
Therapeutic product effect prolonged08.06.01.0540.005644%Not Available
The 2th Page    First    Pre   2    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene